Ed Mathers joined New Enterprise Associates (NEA) as a partner in August 2008, focusing on biotechnology and specialty pharmaceuticals investments. He most recently served as Executive Vice President, Corporate Development and Venture, at MedImmune Inc. In this role, he was a member of the leadership team that executed the sale of the company to AstraZeneca for $15.6 billion in 2007. While at MedImmune, Mr. Mathers was responsible for the company’s corporate and business development activities and led the company’s venture capital subsidiary, MedImmune Ventures, Inc.
Before joining MedImmune in 2002, he was Vice President, Marketing, Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Mr. Mathers spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline), where he held positions of increasing responsibility. Mr. Mathers is a director of Liquidia Technologies, chairman of Ra Pharmaceuticals, Rhythm Pharmaceuticals, Envisia Therapeutics, Synlogic, Mirna Therapeutics, Lumos Pharma, Amplyx Pharmaceuticals, Senti Biosciences, and ObsEva. He earned his bachelor’s degree in chemistry from North Carolina State University.